1. Scrip
  2. >>Business

AstraZeneca Hands LEO Dermatology Potential

 
• By Lubna Ahmed

AstraZeneca PLC is handing over two pipeline skin disease medicines, tralokinumab and brodalumab, to LEO Pharma for an upfront payment of $115m while it focuses on other key therapy areas. The UK big pharma has also put an end to its license with Valeant Pharmaceuticals for brodalumab in Europe in favor of its new partner.

AstraZeneca PLC has struck a strategic partnership with Leo Pharma AS in which the Danish company will acquire the global licence to tralokinumab, an anti-IL-13 monoclonal antibody for atopic dermatitis. AstraZeneca has also terminated the license for Valeant Pharmaceuticals International Inc.’s right to develop and commercialize IL-17 receptor monoclonal antibody brodalumab in Europe. Under this new agreement, dermatology focused LEO Pharma has been given the exclusive licence to brodalumab for patients with moderate-to-severe plaque psoriasis in Europe. (Also see "AstraZeneca Unburdens Itself Of Brodalumab" - Scrip, 1 September, 2015.)

LEO will make an upfront payment to AstraZeneca of $115m for the rights to tralokinumab in dermatitis and any future...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Sanofi Doubles Down On Respiratory Vaccines With Vicebio Buy

 
• By Kevin Grogan

The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: J&J delivers in Q2 despite Stelara drop; Sarepta cuts jobs as Elevidys slumps; AI is inevitable but needs to be applied appropriately; China’s mid-cap companies thrive; and a look behind Glenmark’s landmark trispecific deal.

Chief Strategist O’Hara On Novavax’s Partnership-Focused Approach

 
• By Mandy Jackson

A deal last year with Sanofi relieved Novavax of commercial costs for the COVID-19 vaccine Nuvaxovid, allowing the company to focus on R&D and finding partners for its other vaccines.

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By Kevin Grogan

The Austrian firm is delisting from the NASDAQ and closing down.

More from Scrip

Chief Strategist O’Hara On Novavax’s Partnership-Focused Approach

 
• By Mandy Jackson

A deal last year with Sanofi relieved Novavax of commercial costs for the COVID-19 vaccine Nuvaxovid, allowing the company to focus on R&D and finding partners for its other vaccines.

Pharma Gets A Compatriot At CDER With Tidmarsh Appointment To Top Spot

 
• By Jessica Merrill

Drug manufacturers may find comfort in the appointment of former biotech CEO and entrepreneur George Tidmarsh to lead the FDA’s Center for Drug Evaluation and Research.

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results

 
• By Alaric DeArment

The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.